Madrigal Pharmaceuticals, Inc. (MDGL) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Madrigal Pharmaceuticals, Inc. (MDGL) closed at USD 459.81 on 2026-10-15, a change of +9.1 % over the past year, with a market capitalization of USD 10.39B.

Madrigal Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Madrigal Pharmaceuticals, Inc. key figures

Previous close

USD 459.81 (2026-10-15)

1-year change

+9.1 %

Market cap

USD 10.39B

Enterprise value

USD 9.9B

P/E ratio (trailing)

-35.00

P/E ratio (forward)

46.73

EPS (trailing)

-12.85

EPS (forward)

9.63

PEG ratio

n/a

Price to book

19.83

Revenue growth

71.2 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

10.83

Employees

915

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Madrigal Pharmaceuticals, Inc. and compare it with other stocks.